August 25, 2020

News Release

Company: Olympus Corporation
Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations

Notice Concerning Global Voluntary Recall of Endoscopic Products

Olympus Corporation (“Olympus”) hereby announces that Olympus has decided to carry out a voluntary recall (“the recall”) of the Olympus BF TYPE Q180 (“BF-Q180”) Bronchovideoscope and the Olympus CHF TYPE CB30S (“CHF-CB30S”) Choledochofiberscope sold by the Olympus Group today. Olympus sincerely apologizes for any inconvenience and concern this may cause to healthcare professionals, patients, and other stakeholders.

1. Reason for the recall

Olympus regularly conducts voluntary post-market surveillance of our medical products ("voluntary surveillance") to ensure the quality, safety, and effectiveness of the products we sell and upon which our healthcare partners rely.

Based on the said voluntary surveillance, regarding the BF-Q180 is associated with a higher rate of patient infections than other comparable Olympus bronchoscopes. Regarding the CHF-CB30S, Olympus determined that there is a possibility of equipment parts remaining behind in the patient's body after procedure and, if such happens, may result in serious condition that could require surgery, etc. Olympus has decided to execute the recall in light of our quality standards, placing top priority on patient safety.

2. Affected products

Product name	Applications	Shipment date	Units in operation
EVIS EXERA II BRONCHOVIDEOSCOPE OLYMPUS BF TYPE Q180	Visual examination, diagnosis and treatment of the airways and tracheobronchialtree	April 2005 - March 2019	Approx. 3,900 units
OES CHOLEDOCHOFIBERSCOPE OLYMPUS CHF TYPE CB30S	Visual examination, diagnosis and treatment of the biliary tract area	April 1998 - March 2020	Approx. 250 units

Notes 1: Currently, both products are no longer manufactured or sold.

Notes 2: A detailed investigation is in progress to determine the volume of products subject to the recall.

3. Measures to be taken

Olympus has identified all the users of BF-Q180 and CHF-CB30S. Notifications are being sent to medical institutions that may currently own or may be using the products subject to the recall.

4. Impacts on business results

Olympus is investigating the costs associated with this recall, however, at current, approximately JPY 5 billion are expected to be booked as "Cost of Sales" into business results for the second quarter of the fiscal year ending March 31, 2021.

The forecast of consolidated financial results for the fiscal year ending March 31, 2021 is undetermined since it is difficult to make a reasonable calculation due to the impact of COVID-19. Olympus will promptly disclose such information once the forecast of consolidated financial results can be calculated.